Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2025)
Quarterly results put Income from Continuing Operations at 3437601.0 for Q3 2025, down 132.97% from a year ago — trailing twelve months through Sep 2025 was 9991657.0 (down 47.24% YoY), and the annual figure for FY2024 was 15585619.0, down 85.94%.
Monopar Therapeutics has reported Income from Continuing Operations over the past 9 years, most recently at 3437601.0 for Q3 2025.
- Income from Continuing Operations reached 3437601.0 in Q3 2025 per MNPR's latest filing, down from 2453526.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1475558.0 in Q3 2024 and bottomed at 14050593.0 in Q4 2022.
- Median Income from Continuing Operations over the past 5 years was 2453526.0 (2025), compared with a mean of 2997699.94.
- The largest annual shift saw Income from Continuing Operations crashed 424.06% in 2022 before it skyrocketed 35.0% in 2024.
- Over 5 years, Income from Continuing Operations stood at 2681118.0 in 2021, then plummeted by 424.06% to 14050593.0 in 2022, then surged by 86.1% to 1953734.0 in 2023, then increased by 24.47% to 1475558.0 in 2024, then tumbled by 132.97% to 3437601.0 in 2025.
- Business Quant data shows Income from Continuing Operations for MNPR at 3437601.0 in Q3 2025, 2453526.0 in Q2 2025, and 2624972.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.64 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -14.05 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.76 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -2.26 Mn |
| Sep 30, 2020 | -1.65 Mn |
| Jun 30, 2020 | -1.46 Mn |
| Mar 31, 2020 | -1.14 Mn |
| Dec 31, 2019 | -1.22 Mn |
| Sep 30, 2019 | -759,448.00 |
| Jun 30, 2019 | -932,109.00 |
| Mar 31, 2019 | -1.41 Mn |
| Dec 31, 2018 | -926,358.00 |
| Sep 30, 2018 | -667,532.00 |
| Jun 30, 2018 | -667,532.00 |
| Mar 31, 2018 | -897,260.00 |
| Dec 31, 2017 | -736,800.00 |
| Sep 30, 2017 | -14.90 Mn |
| Jun 30, 2017 | -594,957.00 |
| Mar 31, 2017 | -373,839.00 |